The global spatial proteomics market was valued at USD 612.4 million in 2025. It is estimated at USD 684.7 million in 2026 and is projected to reach USD 2.18 billion by 2036, at a CAGR of 12.3% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering immuno-oncology and translational research demand, clinical trial biomarker testing, imaging and barcoding technologies, platform benchmarking, regulatory pathways, pricing, mergers and restructuring, the supplier landscape, and future growth opportunities.
The market covers the instruments, consumables, software, and services used to measure many proteins at once in intact tissue sections and cells while keeping track of where each protein sits. Products in scope include cyclic and spectral immunofluorescence imagers, imaging mass cytometry and MALDI systems, digital spatial profilers and in situ multiomics imagers that read barcoded antibodies, antibody panels and reagents, analysis and AI software, and contract services. Single-plex and low-plex chromogenic immunohistochemistry used in routine diagnostics, spatial transcriptomics products that do not detect protein, and bulk or dissociated single-cell proteomics products are excluded.
Conventional immunohistochemistry reads only one or a few markers per section, whereas current spatial platforms read dozens to hundreds of proteins on the same slide and show how tumor, immune, and stromal cells are arranged and interact. Bruker has shown datasets of 208 proteins from CellScape XR, and the Quanterix PhenoCode Discovery IO60 panel profiles 60 immuno-oncology biomarkers in one assay. Near-term demand is mixed: Quanterix reported 34% revenue growth in the second quarter of 2026 but cut its full-year guidance, Bruker reported soft U.S. academic demand in the same quarter, and Bio-Techne reported a 2.4% revenue decline in its Diagnostics and Spatial Biology segment for the fiscal year ended June 2026.
High capital costs for platforms, together with the per-sample cost of high-plex antibody panels, imaging time, and data analysis, hold back adoption in smaller laboratories and in emerging economies, where many users rely on core facilities or outside service providers. Tight academic and pharmaceutical research budgets are delaying instrument purchases and lengthening sales cycles. The lack of common standards for panels, protocols, and analysis makes results hard to compare across laboratories, and validating high-plex antibody panels for each tissue and fixation type is slow and costly.
Clinical translation is a significant opportunity, as spatial biomarkers that capture tumor-immune interactions could improve treatment prediction and support companion diagnostics and precision pathology; PreludeDx announced its AidaBREAST multi-omic breast cancer assay on the Quanterix platform in April 2026. AI-based cell segmentation, phenotyping, and pattern recognition, outsourced spatial studies for pharmaceutical sponsors, and new spatial biology core facilities in China, Japan, South Korea, and Singapore offer further openings. Key trends include consolidation among spatial biology providers, the move toward automated, higher-throughput instruments, and measuring protein and RNA on the same tissue section.
By offering, the spatial proteomics market is segmented into instruments, consumables, software, and services. Consumables are expected to hold the largest share in 2026, since every experiment uses antibody panels, conjugated antibodies, staining reagents, and kits, the installed base of imaging and profiling platforms keeps growing, and restrained capital spending in 2026 gives recurring purchases more weight than new instruments. Software is set to record the highest CAGR, as spatial datasets keep growing in size and complexity, automated segmentation and phenotyping are becoming essential, and AI is increasingly used to find spatial patterns and biomarkers. Services are growing as drug developers outsource biomarker work.
By technology, the spatial proteomics market is segmented into multiplexed immunofluorescence, mass spectrometry-based imaging, oligonucleotide-barcoded antibody technologies, and other technologies. Multiplexed immunofluorescence is expected to account for the largest share in 2026, given its broad installed base, its fit with standard pathology workflows, and its use in both discovery and translational studies. Oligonucleotide-barcoded antibody technologies are set to grow the fastest, as they read very high numbers of proteins and can detect protein and RNA together, as shown by Bruker's linked GeoMx and CosMx workflows and the Quanterix Spatial Molecular Barcoding kit for the PhenoCycler Fusion. In mass spectrometry-based imaging, Standard BioTools agreed in July 2026 to sell its mass cytometry business, including the Hyperion platform, to Multiplex Bio.
By sample type, the spatial proteomics market is segmented into FFPE tissue, fresh-frozen tissue, and other samples. FFPE tissue is expected to hold the largest share in 2026 and to record the highest CAGR during the forecast period, because it is the standard format for pathology archives, most clinical trial biopsies are stored this way, and translational and diagnostic uses of spatial proteomics depend on FFPE-compatible workflows.
By application, the spatial proteomics market is segmented into translational research, drug discovery & development, basic research, and clinical research & diagnostics. Translational research is expected to account for the largest share in 2026, as academic medical centers and cancer institutes use spatial protein data to study disease mechanisms, find biomarkers, and relate tissue features to patient outcomes. Clinical research & diagnostics is set to grow at the highest CAGR, supported by wider adoption of spatial biomarkers in trials, new panels built on clinically validated antibodies, and partnerships such as those of 10x Genomics with Dana-Farber Cancer Institute, the Cleveland Clinic, and Lausanne University Hospital.
By indication, the spatial proteomics market is segmented into oncology, immunology & inflammatory diseases, neuroscience, infectious diseases, and other indications. Oncology is expected to account for the largest share in 2026, reflecting the scale of immuno-oncology research and drug development, the importance of the tumor microenvironment in immunotherapy response, and the availability of dedicated oncology panels such as Bio-Techne's 21-plex panel for lymphoid malignancies. Immunology & inflammatory diseases and neuroscience are also drawing more spatial work, as combined protein and RNA readouts give researchers a fuller view of cell identity and function in complex tissues.
By end user, the spatial proteomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and hospitals & clinical laboratories. Academic & research institutes are expected to hold the largest share in 2026, as universities, research institutes, and shared core facilities own much of the installed base of spatial platforms. Pharmaceutical & biotechnology companies are set to grow at the highest CAGR, as spatial biomarkers become part of immunotherapy pipelines and trials, which need validated, high-throughput workflows. Contract research organizations are also expected to grow strongly as sponsors outsource spatial biomarker studies instead of buying their own instruments.
In 2026, North America is expected to hold the largest share of the global spatial proteomics market, supported by its concentration of cancer centers, academic medical centers, and drug developers, and by the presence of leading providers such as Quanterix, 10x Genomics, RareCyte, Vizgen, and Bruker Spatial Biology. Hospital partnerships and trial biomarker testing are widening use in the U.S., although weak academic spending in 2026, as noted by Bruker and Quanterix, is likely to slow near-term instrument sales. Canada adds demand through cancer institutes and academic core facilities. Europe holds a significant share, led by Germany, home to Miltenyi Biotec and Merck KGaA and a major base for Bruker, and Switzerland, home to Lunaphore and Lausanne University Hospital, with the U.K., France, the Netherlands, and Spain also contributing.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding cancer research, a growing biopharmaceutical industry, and new core facilities. Bruker saw strong orders from Chinese academic and government buyers in the second quarter of 2026, according to the company. China is expected to lead the region, with strong growth also expected in Japan, South Korea, Singapore, and Australia, and India emerging as a new market. Latin America and the Middle East & Africa account for smaller shares, with demand tied to academic cancer research and precision oncology programs in Brazil, Saudi Arabia, and the UAE.
Large life science tools and spatial biology companies hold a significant part of the spatial proteomics market, competing with specialist imaging developers, reagent suppliers, software firms, and service providers. Vendors compete on plex, throughput, automation, FFPE compatibility, RNA integration, panel range, and AI software. Consolidation is reshaping the field: Bruker bought NanoString in 2024, Quanterix closed its purchase of Akoya Biosciences in July 2025, Merck KGaA agreed in June 2026 to acquire Bio-Techne, and Vizgen, which includes Ultivue, raised Series E funding in January 2026. Recent launches include Bruker's CellScape XR, RareCyte's Orion HT and Orion LE, and the 10x Genomics Atera platform.
Key companies profiled in the report include Bruker Corporation (U.S.), Quanterix Corporation (U.S.), Bio-Techne Corporation (U.S.), 10x Genomics, Inc. (U.S.), Danaher Corporation (Leica Microsystems) (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), RareCyte, Inc. (U.S.), and Vizgen, Inc. (U.S.).
The market covers the instruments, consumables, software, and services used to measure many proteins at once in intact tissue sections and cells while keeping track of where each protein sits. Products in scope include cyclic and spectral immunofluorescence imagers, imaging mass cytometry and MALDI systems, digital spatial profilers and in situ multiomics imagers that read barcoded antibodies, antibody panels and reagents, analysis and AI software, and contract services. Single-plex and low-plex chromogenic immunohistochemistry used in routine diagnostics, spatial transcriptomics products that do not detect protein, and bulk or dissociated single-cell proteomics products are excluded.
Conventional immunohistochemistry reads only one or a few markers per section, whereas current spatial platforms read dozens to hundreds of proteins on the same slide and show how tumor, immune, and stromal cells are arranged and interact. Bruker has shown datasets of 208 proteins from CellScape XR, and the Quanterix PhenoCode Discovery IO60 panel profiles 60 immuno-oncology biomarkers in one assay. Near-term demand is mixed: Quanterix reported 34% revenue growth in the second quarter of 2026 but cut its full-year guidance, Bruker reported soft U.S. academic demand in the same quarter, and Bio-Techne reported a 2.4% revenue decline in its Diagnostics and Spatial Biology segment for the fiscal year ended June 2026.
Market Dynamics
Immuno-oncology is a major driver of the spatial proteomics market, because the arrangement of tumor, immune, and stromal cells strongly influences how patients respond to checkpoint inhibitors and other immunotherapies, and spatial biomarkers predict that response better than single-marker tests. Drug developers add further demand as they use high-plex tissue biomarkers to select patients, confirm mechanism of action, and get the most information from small biopsies, with RareCyte's Orion HT system already used by Novartis subsidiary Navigate BioPharma Services for clinical trial biomarker testing. Steady gains in plex, imaging area, and speed, together with workflows that link protein data with spatial transcriptomics and digital pathology, are widening the range of research questions these platforms can answer.High capital costs for platforms, together with the per-sample cost of high-plex antibody panels, imaging time, and data analysis, hold back adoption in smaller laboratories and in emerging economies, where many users rely on core facilities or outside service providers. Tight academic and pharmaceutical research budgets are delaying instrument purchases and lengthening sales cycles. The lack of common standards for panels, protocols, and analysis makes results hard to compare across laboratories, and validating high-plex antibody panels for each tissue and fixation type is slow and costly.
Clinical translation is a significant opportunity, as spatial biomarkers that capture tumor-immune interactions could improve treatment prediction and support companion diagnostics and precision pathology; PreludeDx announced its AidaBREAST multi-omic breast cancer assay on the Quanterix platform in April 2026. AI-based cell segmentation, phenotyping, and pattern recognition, outsourced spatial studies for pharmaceutical sponsors, and new spatial biology core facilities in China, Japan, South Korea, and Singapore offer further openings. Key trends include consolidation among spatial biology providers, the move toward automated, higher-throughput instruments, and measuring protein and RNA on the same tissue section.
Segment Analysis
The report analyzes the market by offering, technology, sample type, application, indication, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the spatial proteomics market is segmented into instruments, consumables, software, and services. Consumables are expected to hold the largest share in 2026, since every experiment uses antibody panels, conjugated antibodies, staining reagents, and kits, the installed base of imaging and profiling platforms keeps growing, and restrained capital spending in 2026 gives recurring purchases more weight than new instruments. Software is set to record the highest CAGR, as spatial datasets keep growing in size and complexity, automated segmentation and phenotyping are becoming essential, and AI is increasingly used to find spatial patterns and biomarkers. Services are growing as drug developers outsource biomarker work.
By technology, the spatial proteomics market is segmented into multiplexed immunofluorescence, mass spectrometry-based imaging, oligonucleotide-barcoded antibody technologies, and other technologies. Multiplexed immunofluorescence is expected to account for the largest share in 2026, given its broad installed base, its fit with standard pathology workflows, and its use in both discovery and translational studies. Oligonucleotide-barcoded antibody technologies are set to grow the fastest, as they read very high numbers of proteins and can detect protein and RNA together, as shown by Bruker's linked GeoMx and CosMx workflows and the Quanterix Spatial Molecular Barcoding kit for the PhenoCycler Fusion. In mass spectrometry-based imaging, Standard BioTools agreed in July 2026 to sell its mass cytometry business, including the Hyperion platform, to Multiplex Bio.
By sample type, the spatial proteomics market is segmented into FFPE tissue, fresh-frozen tissue, and other samples. FFPE tissue is expected to hold the largest share in 2026 and to record the highest CAGR during the forecast period, because it is the standard format for pathology archives, most clinical trial biopsies are stored this way, and translational and diagnostic uses of spatial proteomics depend on FFPE-compatible workflows.
By application, the spatial proteomics market is segmented into translational research, drug discovery & development, basic research, and clinical research & diagnostics. Translational research is expected to account for the largest share in 2026, as academic medical centers and cancer institutes use spatial protein data to study disease mechanisms, find biomarkers, and relate tissue features to patient outcomes. Clinical research & diagnostics is set to grow at the highest CAGR, supported by wider adoption of spatial biomarkers in trials, new panels built on clinically validated antibodies, and partnerships such as those of 10x Genomics with Dana-Farber Cancer Institute, the Cleveland Clinic, and Lausanne University Hospital.
By indication, the spatial proteomics market is segmented into oncology, immunology & inflammatory diseases, neuroscience, infectious diseases, and other indications. Oncology is expected to account for the largest share in 2026, reflecting the scale of immuno-oncology research and drug development, the importance of the tumor microenvironment in immunotherapy response, and the availability of dedicated oncology panels such as Bio-Techne's 21-plex panel for lymphoid malignancies. Immunology & inflammatory diseases and neuroscience are also drawing more spatial work, as combined protein and RNA readouts give researchers a fuller view of cell identity and function in complex tissues.
By end user, the spatial proteomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and hospitals & clinical laboratories. Academic & research institutes are expected to hold the largest share in 2026, as universities, research institutes, and shared core facilities own much of the installed base of spatial platforms. Pharmaceutical & biotechnology companies are set to grow at the highest CAGR, as spatial biomarkers become part of immunotherapy pipelines and trials, which need validated, high-throughput workflows. Contract research organizations are also expected to grow strongly as sponsors outsource spatial biomarker studies instead of buying their own instruments.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 18 countries and four rest-of-region groups. The regional analysis of the spatial proteomics market considers cancer research activity, biopharmaceutical development, academic and core facility funding, the presence of platform providers, and progress toward clinical use of spatial assays.In 2026, North America is expected to hold the largest share of the global spatial proteomics market, supported by its concentration of cancer centers, academic medical centers, and drug developers, and by the presence of leading providers such as Quanterix, 10x Genomics, RareCyte, Vizgen, and Bruker Spatial Biology. Hospital partnerships and trial biomarker testing are widening use in the U.S., although weak academic spending in 2026, as noted by Bruker and Quanterix, is likely to slow near-term instrument sales. Canada adds demand through cancer institutes and academic core facilities. Europe holds a significant share, led by Germany, home to Miltenyi Biotec and Merck KGaA and a major base for Bruker, and Switzerland, home to Lunaphore and Lausanne University Hospital, with the U.K., France, the Netherlands, and Spain also contributing.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding cancer research, a growing biopharmaceutical industry, and new core facilities. Bruker saw strong orders from Chinese academic and government buyers in the second quarter of 2026, according to the company. China is expected to lead the region, with strong growth also expected in Japan, South Korea, Singapore, and Australia, and India emerging as a new market. Latin America and the Middle East & Africa account for smaller shares, with demand tied to academic cancer research and precision oncology programs in Brazil, Saudi Arabia, and the UAE.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.Large life science tools and spatial biology companies hold a significant part of the spatial proteomics market, competing with specialist imaging developers, reagent suppliers, software firms, and service providers. Vendors compete on plex, throughput, automation, FFPE compatibility, RNA integration, panel range, and AI software. Consolidation is reshaping the field: Bruker bought NanoString in 2024, Quanterix closed its purchase of Akoya Biosciences in July 2025, Merck KGaA agreed in June 2026 to acquire Bio-Techne, and Vizgen, which includes Ultivue, raised Series E funding in January 2026. Recent launches include Bruker's CellScape XR, RareCyte's Orion HT and Orion LE, and the 10x Genomics Atera platform.
Key companies profiled in the report include Bruker Corporation (U.S.), Quanterix Corporation (U.S.), Bio-Techne Corporation (U.S.), 10x Genomics, Inc. (U.S.), Danaher Corporation (Leica Microsystems) (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), RareCyte, Inc. (U.S.), and Vizgen, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global spatial proteomics market.
- Explains how immuno-oncology research, clinical trial biomarker testing, and spatial multiomics are shaping demand for platforms, panels, and software.
- Assesses the impact of constrained research budgets, high per-sample costs, and the lack of standardization on adoption.
- Identifies high-growth opportunities across offering, technology, sample type, application, indication, end user, and region.
- Tracks barcoded antibody methods, AI image analysis, and automated workflows.
- Benchmarks leading companies by platform capabilities, plex, throughput, panel portfolios, and recent acquisitions and launches.
- Supports product planning, partnering, acquisition screening, service expansion, and market entry decisions for technology providers, reagent suppliers, service companies, and investors.
Key Questions Answered
- How big is the global spatial proteomics market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are constrained academic and pharmaceutical budgets affecting instrument and consumable demand?
- Which offering, technology, sample type, application, indication, and end-user segments will grow the fastest?
- How quickly will oligonucleotide-barcoded antibody technologies and protein-RNA workflows be adopted?
- What role will spatial biomarkers play in clinical trials, companion diagnostics, and precision pathology?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how are acquisitions and restructuring changing the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Spatial Proteomics Market, by Offering
6. Spatial Proteomics Market, by Technology
7. Spatial Proteomics Market, by Sample Type
8. Spatial Proteomics Market, by Application
9. Spatial Proteomics Market, by Indication
10. Spatial Proteomics Market, by End User
11. Spatial Proteomics Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Bruker Corporation
- Quanterix Corporation
- Bio-Techne Corporation
- 10x Genomics, Inc.
- Danaher Corporation
- Miltenyi Biotec B.V. & Co. KG
- RareCyte, Inc.
- Vizgen, Inc.
